Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,366,840
  • Shares Outstanding, K 1,246,266
  • Annual Sales, $ 27,116 M
  • Annual Income, $ 5,665 M
  • EBIT $ 823 M
  • EBITDA $ 3,516 M
  • 60-Month Beta 0.18
  • Price/Sales 4.25
  • Price/Cash Flow 10.18
  • Price/Book 6.17

Options Overview Details

View History
  • Implied Volatility 23.92% ( -1.62%)
  • Historical Volatility 22.93%
  • IV Percentile 61%
  • IV Rank 37.25%
  • IV High 33.98% on 08/05/24
  • IV Low 17.95% on 11/07/24
  • Put/Call Vol Ratio 0.94
  • Today's Volume 7,287
  • Volume Avg (30-Day) 12,257
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 239,960
  • Open Int (30-Day) 239,104

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.67
  • Number of Estimates 10
  • High Estimate 1.99
  • Low Estimate 1.13
  • Prior Year 1.72
  • Growth Rate Est. (year over year) -2.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
88.07 +5.11%
on 11/21/24
94.65 -2.20%
on 12/11/24
+3.94 (+4.45%)
since 11/20/24
3-Month
81.83 +13.13%
on 09/26/24
98.90 -6.40%
on 11/11/24
+8.63 (+10.28%)
since 09/20/24
52-Week
62.07 +49.14%
on 05/31/24
98.90 -6.40%
on 11/11/24
+13.98 (+17.79%)
since 12/20/23

Most Recent Stories

More News
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have gained 15.4% in a year against the industry’s decline of 10.8%. The stock has...

MRK : 98.05 (-1.48%)
GILD : 92.57 (+1.62%)
GSK : 33.60 (+0.51%)
New Vaccine Technologies Lead the Charge as Global Immunization Efforts Evolve

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – According to the World Health...

PCVX : 86.53 (+0.37%)
BVAXF : 0.0475 (+2.15%)
BIOV.CN : 0.0650 (+8.33%)
GILD : 92.57 (+1.62%)
GOVX : 2.29 (-1.29%)
ARCT : 15.48 (+4.31%)
4 Big Drug Stocks That May Continue to Outperform in 2025

The drug and biotech sector saw a strong first half of 2024, driven by an increase in mergers and acquisitions (M&A), robust earnings, and pipeline and regulatory successes. The Zacks Large Cap Pharmaceuticals...

LLY : 767.76 (+1.35%)
VRTX : 397.27 (+0.16%)
GILD : 92.57 (+1.62%)
ABBV : 175.58 (+2.37%)
Biogen Stock: Is BIIB Underperforming the Healthcare Sector?

Biogen has recently lagged behind the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on the stock's long-term growth potential.

XLV : 138.00 (+1.26%)
GILD : 92.57 (+1.62%)
BIIB : 146.47 (-0.62%)
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases

Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe (PFS) of the ophthalmology drug Vabysmo (faricimab).The regulatory body approved Vabysmo PFS for use in the treatment...

GILD : 92.57 (+1.62%)
REGN : 701.85 (-0.90%)
RHHBY : 34.5000 (+0.76%)
BMY : 57.33 (+1.83%)
3 Penny Stocks With 10% to 210% Upside Potential

Investors should consider these three penny stocks for their solid upside potential, even after this year's rally.

CGEN : 1.5300 (+0.66%)
MAPS : 1.6300 (+11.64%)
AZN : 65.35 (+1.41%)
$SPX : 5,930.85 (+1.09%)
GCG25 : 2,645.1s (+1.42%)
NGD : 2.51 (+1.21%)
GILD : 92.57 (+1.62%)
Bristol Myers Stock Surges 36.5% in Six Months: Time to Buy or Sell?

The going has been pretty good for Bristol Myers BMY in the past six months. Shares of this biotech giant have rallied 36.4% in the said timeframe against the industry’s decline of 1.8%. The stock has...

GILD : 92.57 (+1.62%)
PFE : 26.36 (+2.29%)
BMY : 57.33 (+1.83%)
Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%

Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 billion stock repurchase plan ended in the fourth quarter of 2024.The board...

LLY : 767.76 (+1.35%)
EXEL : 33.29 (-1.16%)
GILD : 92.57 (+1.62%)
PFE : 26.36 (+2.29%)
Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences

Monday, December 9, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and...

INTC : 19.52 (+2.41%)
LLY : 767.76 (+1.35%)
GILD : 92.57 (+1.62%)
ABBV : 175.58 (+2.37%)
COIN : 278.71 (+1.75%)
MRVL : 111.90 (+2.56%)
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for...

ALNY : 245.44 (+2.75%)
GILD : 92.57 (+1.62%)
GSK : 33.60 (+0.51%)
PFE : 26.36 (+2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 96.25
2nd Resistance Point 94.77
1st Resistance Point 93.67
Last Price 92.57
1st Support Level 91.09
2nd Support Level 89.61
3rd Support Level 88.51

See More

52-Week High 98.90
Last Price 92.57
Fibonacci 61.8% 84.83
Fibonacci 50% 80.49
Fibonacci 38.2% 76.14
52-Week Low 62.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar